An evaluation of efficacy and safety of reboxetine in elderly patients affected by "retarded" post-stroke depression: A random, placebo-controlled study

Archives of Gerontology and Geriatrics

Volumn 40, Issue 3, 2005, Pages 275-285

  Rampello, Liborio ^a   Alvano, Alessandro ^a   Chiechio, Santina ^a   Raffaele, Rocco ^a   Vecchio, Ignazio ^a   Malaguarnera, Mariano ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Noradrenaline reuptake inhibitors (NARI); Post stroke depression; Reboxetine

Indexed keywords

NORADRENALIN UPTAKE INHIBITOR; PLACEBO; REBOXETINE;

AGED; ANALYSIS OF VARIANCE; ARTICLE; BECK DEPRESSION INVENTORY; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HAMILTON SCALE; HUMAN; MALE; PRIORITY JOURNAL; RETARDED POST STROKE DEPRESSION; STROKE;

EID: 16244407729     PISSN: 01674943     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.archger.2004.09.004     Document Type: Article

References (60)

1. I. Aben, F. Verhey, A. Honig, J. Lodder, R. Lousberg, and M. Maes Research into the specificity of depression after stroke: a review on an unresolved issue Prog. Neuropsychopharmacol. Biol. Psychiat. 25 2001 671 689
2. E. Aguglia Reboxetine in the maintenance therapy of depressive disorder in the elderly: a long-term open study Int. J. Geriatr. Psychiat. 15 2000 784 793
3. G. Andersen, K. Vestergaard, and L. Lauritzen Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram Stroke 25 1994 1099 1104
4. G. Andersen, K. Vestergaard, M. Ingemann-Nielsen, and L. Lauritzen Risk factors for post-stroke depression Acta Psychiatr. Scand. 92 1995 193 198
5. V. Andreoli, G. Carbognin, A. Abati, and G. Vantini Reboxetine in the treatment of depression in the elderly: pilot study J. Geriatr. Psychiat. Neurol. 12 1999 206 210
6. T.A. Ban, P. Gaszner, E. Aguglia, R. Batista, A. Castillo, A. Lipcsey, J.P. Macher, A. Torres-Ruiz, and L. Vergara Clinical efficacy of reboxetine: a comparative study with desipramine, with methodological considerations Hum. Psychopharmacol. Clin. Exp. 13 Suppl. 1 1998 29 39
7. A.M. Barret Treatment of poststroke depression J. Am. Med. Assoc. 284 2000 959
8. J.F. Bergmann, J.P. Laneury, P. Duchene, J.C. Fleishaker, G. Houin, and J.M. Segrestaa Pharmacokinetics of reboxetine in healthy, elderly volunteers Eur. J. Drug. Metab. Pharmacokinet. 25 2000 195 198
9. H. Berzewski, M. Van Moffaert, and C.A. Gagiano Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes Eur. Neuropsychopharmacol. 7 Suppl. 1 1997 37 47
10. J.C. Breitner Vascular depression: new light on an established idea? J. Neurol. Neurosurg. Psychiat. 70 2001 3
11. G.D. Burrows, K.P. Maguire, and T.R. Norman Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review J. Clin. Psychiat. 9 Suppl. 14 1998 4 7
12. A.J. Carson, S. MacHale, K. Allen, S.M. Lawrie, M. Dennis, A. House, and M. Sharpe Depression after stroke and lesion location: a systematic review Lancet 8 356 2000 122 126
13. F.B. Charatan, and A. Fisk Mental and emotional results of strokes N. Y. State J. Med. 78 1978 1403 1405
14. A. Dubini, M. Bosc, and V. Polin Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning J. Psychopharmacol. 11 Suppl. 4 1997 17 23
15. S. Fruhwald, H. Loffler, and U. Baumhackl Depression after cerebrovascular injury Review and differentiation from other psychiatric complications Fortschr. Neurol. Psychiatr. 67 1999 155 162
16. G. Gainotti, A. Azzoni, F. Gasparini, C. Marra, and C. Razzano Relation of lesion location to verbal and non verbal mood measures in stroke patients Stroke 28 1997 2145 2149
17. G. Gainotti, G. Antonucci, C. Marra, and S. Paolucci Relation between depression after stroke, antidepressant therapy, and functional recovery J. Neurol. Neurosurg. Psychiat. 71 2001 258 261
18. J.I. Gonzalez Torrecillas, J. Mendlewicz, and A. Lobo Analysis of intensity of post-stroke depression and its relationship with the cerebral lesion location Med. Clin. (Barc.) 109 1997 241 244
19. P.J. Goodnick, and M. Hernandez Treatment of depression in comorbid medical illness Expert. Opin. Pharmacother. 1 2000 1367 1384
20. Y. Gustafson, I. Nilsson, M. Mattsson, M. Astrom, and G. Bucht Epidemiology and treatment of post-stroke depression Drugs Aging 7 1995 298 309
21. M. Hermann, and C.W. Wallesh Depressive changes in stroke patients Int. Disabil. Stud. 3 1993 55 66
22. I. Hindmarch The effects of antidepressants on psychomotor function with particular reference to reboxetine Eur. Neuropsychopharmacol. 7 Suppl. 1 1997 17 21
23. S. Johnson, and F.N. Johnson Reboxetine. Pharmacotherapy 2001 Marsen Press
24. O.M. Jolobe Depression and its relation to lesion location after stroke J. Neurol. Neurosurg. Psychiat. 65 1998 410
25. F. Karege, P. Bovier, J. Widmer, J.M. Gaillard, and R. Tissot Platelet membrane alpha 2-adrenergic receptors in depression Psychiat. Res. 43 1992 243 252
26. S. Kasper, N. El Giamal, and E. Hilger Reboxetine: the first selective noradrenaline re-uptake inhibitor Expert. Opin. Pharmacother. 1 2000 771 782
27. C. Katona, E. Bercoff, E. Chiu, P. Tack, M. Versiani, and H. Woelk Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial J. Affect. Disord. 55 1999 203 213
28. S.H. Kennedy, R.W. Lam, N.L. Cohen, M. Rosenbluth, S.T.H. Sokolov, R.S. McIntyre, P. Chue, G. Craigen The Canadian Network for Mood and Anxiety Treatments (CANMAT) Reboxetine: a preliminary report on its use through the Special Access Program J. Psychiat. Neurosci. 27 2002 418 422
29. B.E. Leonard The role of noradrenaline in depression: a review J. Psychopharmacol. 11 Suppl. 4 1997 39 47
30. C.G. Lyketsos, G.J. Treisman, J.R. Lipsey, P.L. Morris, and R.G. Robinson Does stroke cause depression? J. Neuropsychiat. Clin. Neurosci. 10 1998 103 107
31. J.V.V. Maas Biogenic amines and depression Biochemical and pharmacological separation of two types of depression Arch. Gen. Psychiat. 32 1975 1357 1361
32. J. Massana, H.J. Moller, G.D. Burrows, and R.M. Montenegro Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder Int. Clin. Psychopharmacol. 14 1999 73 80
33. H.S. Mayberg, R.G. Robinson, and D.F. Wong Pet imaging of cortical serotonin receptors following stroke: lateralized changes and relationship to depression Am. J. Psychiat. 145 1998 937 943
34. S.A. Montgomery Reboxetine: additional benefits to the depressed patient J. Psychopharmacol. 11 Suppl. 4 1997 9 15
35. S.A. Montgomery Chairman's overview The place of reboxetine in antidepressant therapy J. Clin. Psychiat. 59 Suppl. 14 1998 26 29
36. M. Mucci Reboxetine: a review of antidepressant tolerability J. Psychopharmacol. 11 Suppl. 4 1997 33 37
37. C. Muldoon The safety and tolerability of citalopram Int. Clin. Psychopharmacol. 11 Suppl. 1 1996 35 40
38. Paolucci, S., 1999. The post-stroke depression (PSD). XXXI Congresso S.I.N.
39. M. Patris, J.M. Bouchard, T. Bougerol, J.F. Charbonnier, J.F. Chevalier, G. Clerc, C. Cyran, P. Van Amerongen, O. Lemming, and H.E. Petersen Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice Int. Clin. Psychopharmacol. 11 1996 129 136
40. J.E. Piletz, A.E. Halaris, D. Chikkala, and Y. Qu Platelet I1-imidazoline binding sites are decreased by two dissimilar antidepressant agents in depressed patients J. Psychiat. Res. 30 1996 169 184
41. I. Poggesi, C. Pellizzoni, and J.C. Fleishaker Pharmacokinetics of reboxetine in elderly patients with depressive disorders Int. J. Clin. Pharmacol. Ther. 38 2000 254 259
42. R. Ramasubbu, A. Flint, G. Brown, G. Awad, and S. Kennedy Diminished serotonin-mediated prolactin responses in nondepressed stroke patients compared with healthy normal subjects Stroke 29 1998 1293 1298
43. L. Rampello, G. Nicoletti, and R. Raffaele Dopaminergic hypothesis for retarded depression: a symptom profile for predicing therapeutical responses Acta Psychiat. Scand. 84 1991 552 554
44. L. Rampello, G. Nicoletti, R. Raffaele, and F. Drago Comparative effects of Amitriptyline and Amineptine in patients affected by anxious depression Neuropsycobiology 31 1995 130 134
45. L. Rampello, F. Nicoletti, and F. Drago Dopamine and depression Therapeutic implications CNS Drugs 13 2000 35 45
46. S.K. Rigler Management of poststroke depression in older people Clin. Geriatr. Med. 15 1999 765 783
47. M. Riva, N. Brunello, A.C. Rovescalli, R. Galimberti, N. Carfagna, P. Carminati, O. Pozzi, S. Ricciardi, R. Roncucci, A. Rossi, and G. Racagni Effect of reboxetine, a new antidepressant drug, on the central noradrenergic system: behavioural and biochemical studies J. Drug Dev. 1 1989 243 254
48. A.H. Robins Are stroke patients more depressed than other disabled subjects? J. Chronic. Dis. 29 1976 479 482
49. R.G. Robinson Neuropsychiatric consequences of stroke Annu. Rev. Med. 48 1997 217 229
50. R.G. Robinson, P.L.P. Morris, and P. Fedoroff Depression and cerebrovascular disease J. Clin. Psychiat. 51 1990 26 31
51. A.C. Scates, and P.M. Doraiswamy Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression Ann. Pharmacother. 34 2000 1302 1312
52. The Sunnybrook Stroke Study, 2000. Functional and neuroanatomic correlations in poststroke depression. Stroke 31, 637.
53. R. Torta, and C. Berra The depression in the neurological and cardiovascular comordidity Italian Society of Neuropsychopharmacology; Fact News and Views, Masson 3 2002 15 19
54. R.J. Turner, and M. Beiser Major depression and depressive symptomatology among the physically disabled: assessing the role of chronic stress J. Nerv. Ment. Dis. 178 1990 343 350
55. L.N. Venditti, A. Arcelus, H. Birnbaum, P. Greenberg, C.E. Barr, C. Rowland, and T. Williamson The impact of antidepressant use on social functioning: reboxetine versus fluoxetine Int. Clin. Psychopharmacol. 15 2000 279 289
56. M. Versiani, M. Amin, and G. Chouinard Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder J. Clin. Psychopharmacol. 20 2000 28 34
57. J. Vetulani, and F. Sulser Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain Nature 257 1975 495 496
58. L. Wiart, H. Petit, P.A. Joseph, J.M. Mazaux, and M. Barat Fluoxetine in early post-stroke depression A double-blind placebo-controlled study Stroke 31 2000 1829 1832
59. J. Willetts, A. Lippa, and B. Beer Clinical development of citalopram J. Clin. Psychopharmacol. 19 Suppl. 1 1999 36 46
60. E.H. Wong, M.S. Sonders, G. Amara, P.M. Tinholt, M.F. Piercey, W.P. Hoffmann, D.K. Hyslop, S. Franklin, R.D. Porsolt, A. Bonsignori, N. Carfagna, and R.A. McArthur Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor Biol. Psychiat. 47 2000 818 829